|
Publications:
1.
Ahmadibeni,
Y., Parang, K. Solid-supported reagents for synthesis of nucleoside
monothiophosphates, dithiodiphosphates, and trithiotriphosphates.
Curr. Protoc. Nucleic Acid Chem.,
in press.
2.
Agarwal,
H. K., Doncel, G., Parang, K. Synthesis and anti-HIV activities of phosphate
triester derivatives of 3′-fluoro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine.
Tetrahedron Lett.
(2008)
49, 4905-4907.
3.
Ye, G., Tiwari, R., Parang K.
Development of Src tyrosine kinase substrate binding site inhibitors.
Curr. Opin. Investig. Drugs
(2008) 9, 605-613.
4.
Ahmadibeni, Y., Parang, K.
Solid-supported diphosphitylating and triphosphitylating reagents for
nucleoside modification. Curr. Protoc.
Nucleic Acid Chem. (2008)
Chapter 13:Unit13.8.
5.
Penugonda, S., Kumar, A.,
Agarwal, H. K., Parang, K.,
Mehvar, R. Synthesis and in vitro characterization of novel
dextran-methylprednisolone conjugates with peptide linkers: Effects of
linker length on hydrolytic and enzymatic release of methylprednisolone and
its peptidyl intermediates. J. Pharm. Sci.
(2008) 97, 2649-2664.
6.
Ahmadibeni, Y.,
Parang, K. Solid-phase
synthesis of symmetrical 5’,5’-dinucleoside mono-, di-, tri-, and
tetraphosphodiesters. Org. Lett.
(2007)
9, 4483-4486.
7.
Bhandari, R., Saiardi,
A., Ahmadibeni, Y., Snowman, A. M., Resnick, A. C., Kristiansen, T. Z.,
Molina, H., Pandey, A., Werner, Jr. J. K., Juluri, K. R., Xu, Y., Prestwich,
G. D., Parang, K., Snyder, S.
H. Protein pyrophosphorylation by inositol pyrophosphates is a
posttranslational event. Proc. Nat. Acad. Sci. U.S.A.
(2007)
104, 15305-15310.
8.
Chimalakonda, C., Agarwal, H., Kumar,
A., Parang, K., Mehvar, R.
Synthesis, analysis, in vitro characterization, and in vivo disposition of a
lamivudine-dextran conjugate for selective antiviral delivery to the liver.
Bioconjugate Chem. (2007)
18, 2097-2108.
9.
Ye, G., Nam, N. H.,
Saleh, A., Kumar, A., Sun, G., Shenoy,
D. B., Amiji, M. M.,
Parang, K.
Cellular delivery of phosphopeptides with tripodal peptide analogues. J.
Med. Chem. (2007) 50,
3604-3617.
10.
Ahmadibeni, Y., Hanley, M., White,
M., Ayrapetov, M., Lin, X., Sun, G.,
Parang, K. Metal-binding properties of a dicysteine-containing motif
in protein tyrosine kinases. ChemBioChem
(2007) 8, 1592-1605.
11.
Carballeira, N. M.,
O’Neil, R., Parang, K.
Synthesis and antifungal properties of alpha-methoxy and
alpha-hydroxyl substituted 4-thiatetradecanoic acids. Chem. Phys. Lipids
(2007)
150, 82-88.
12.
Ahmadibeni, Y.,
Parang, K., Synthesis and
evaluation of oligodeoxynucleotides containing diphosphodiester
internucleotide linkages. Angew. Chem. Int. Ed. (2007) 46,
4739-4743.
13.
Kumar, A., Wang, Y.,
Lin, X., Sun, G., Parang, K.
Synthesis and evaluation of 3-phenylpyrazolopyrimidine-peptide conjugates as
Src tyrosine kinase inhibitors. ChemMedChem
(2007) 2, 1346-1360.
14.
Agarwal, H. K.,
Parang, K. Application of
solid-phase chemistry for the synthesis of 3’-fluoro-3’-deoxythymidine.
Nucleosides, Nucleotides& Nucleic Acids (2007) 26,
317-322.
15.
Gu, X., Wang, Y., Kumar, A., Ye, G., Parang,
K., Sun, G. Design and evaluation of hydroxamate derivatives as
metal-mediated inhibitors of a protein tyrosine kinase. J. Med. Chem.
(2006)
49,
7532-7539.
16.
Kumar, A., Ye, G., Wang, Y., Lin, X., Sun, G., Parang, K. Synthesis and
structure-activity relationships of linear and conformationally constrained
peptide analogs of CIYKYY as Src tyrosine kinase inhibitors. J. Med.
Chem. (2006) 49, 3395-3401.
17.
Carballeira, N. M.,
Sanabria, D., Cruz, C., Parang, K.,
Wan, B., Franzblau, S. 2,6-Hexadecadiynoic acid and 2,6-nondecadiynoic acid
– Novel synthesized acetylenic fatty acids as potent antifungal agents.
Lipids (2006) 41, 507-511.
18.
Ahmadibeni, Y., Parang, K. “Application of a solid-phase β-triphosphitylating
reagent in the synthesis of nucleoside β-triphosphates. J. Org.
Chem. (2006)
71, 5837-5839.
19.
Ahmadibeni, Y., Parang, K. Solid-phase synthesis of dinucleoside and
nucleoside-carbohydrate phosphodiesters and thiophosphodiesters. J. Org.
Chem. (2006)
71, 6693-6696.
20.
Lee, S., Ayrapetov, M. K., Kemble, D., Parang, K., Sun, G. Docking-based
substrate recognition by the catalytic domain of a protein tyrosine kinase,
the C-terminal Src kinase. J. Biol. Chem. (2006) 281,
8183-8189.
21.
Lin, X., Wang, Y., Ahmadibeni, Y., Parang, K., Sun, G. Structural basis for
domain-domain communication in a protein tyrosine kinase, Csk. J. Mol.
Biol. (2006) 357, 1263-1273.
22.
Ayrapetov, M. K., Wang,
Y.-H., Xiaofeng, L., Gu X.,
Parang,
K., Sun G.
Conformational basis for SH2-pTYR527 binding
in SRC inactivation.
J. Biol. Chem. (2006)
281,
23776-23784.
23.
Kumar, A., Ye, G.,
Ahmadibeni, Y., Parang, K.
Synthesis of polymer-bound 4-acetoxy-3-phenylbenzaldehyde derivatives:
Applications in solid-phase organic synthesis.
J. Org. Chem. (2006) 71, 7915-7918.
24.
Parang K.
Editor. Novel approaches in designing anti-HIV microbicides and anti-HIV
Agents. Curr. Pharm. Des. (2005) 11, 123 pp.
25.
Ahmadibeni Y., Parang K. Selective diphosphorylation,
dithiodiphosphorylation, triphosphorylation, and trithiotriphosphorylation
of unprotected carbohydrates and nucleosides. Org. Lett.
(2005)
7, 5589-5592.
26.
Parang K.,
Sun G. Recent advances in the discovery of Src kinases inhibitors. Expert
Opin. Ther. Patents
(2005) 15,
1183-1207.
27.
Ye G., Ayrapetov M., Nam N. H., Sun G., Parang K. Solid-phase binding assays
of peptides using EGFP-Src SH2 domain fusion protein and biotinylated Src
SH2 domain. Bioorg. Med. Chem. Lett.
(2005)
15, 4994-4997.
28.
Carballeira N. M.,
O’Neill R., Parang K. Total synthesis and further scrunity of the
in vitro antifungal activity of 6-nonadecynoic acid. Arch. Pharm.-Pharm.
Med. Chem. (2005) 338, 441-443.
29.
Ayrapetov M. K., Nam N. H., Ye G. Kumar A., Parang K., Sun G. Functional
diversity of Csk, Chk, and Src SH2 domains due to a single residue
variation. J. Biol. Chem. (2005) 280, 25780-25787.
30.
Parang
K.,
Nam N. H. Sardari S. Preparation of azole monosaccharide as antifungal
agents. PCT Int. Appl. 006860
(2005) 62 pp.
31.
Ahmadibeni Y., Parang K.
Polymer-bound oxathiaphospholane: A solid-phase reagent for regioselective
monothiophosphorylation and monophosphorylation of unprotected nucleosides
and carbohydrates. Org. Lett.
(2005) 7,
1955-1958.
32.
Carballeira N. M.,
O’Neill, R., Parang K. Racemic and optically active
2-methoxy-4-oxatetradecanoic acids: Novel synthetic fatty acids with
selective antifungal properties. Chem. Phys. Lipids
(2005) 136,
47-54.
33.
Parang, K.; Sun, G.; Kumar, A.; Nguyen, N. H.; Wang, Y.-H.; Ye, G.
Bisubstrate inhibitors of protein tyrosine kinases as therapeutic agents.
PCT Int. Appl. WO 117932 (2005), 74 pp.
34.
Hines A. C., Parang K., Kohanski R. A., Hubbard S. R., Cole P. A.
Bisubstrate analog probes for the insulin receptor
protein tyrosine kinase: Molecular yardsticks for analyzing catalytic
mechanism and inhibitor design. Bioorg. Chem.
(2005) 33,
285-297.
35.
Lin X., Ayrapetov M. K., Lee S., Parang K., Sun G. Probing the communication
between the regulatory and catalytic domains of a protein tyrosine kinase,
Csk. Biochemistry (2005) 44, 1561-1567.
36.
Ahmadibeni Y., Parang K.
Solid-phase reagents for selective monophosphorylation of carbohydrates and
nucleosides. J. Org. Chem. (2005) 70, 1100-1103.
37.
Parang K.,
Sun G. Protein kinase inhibitors in drug discovery. Drug Discovery
Handbook, 2005, Wiley-Interscience, New Jersey, Ed. Gad, S. C.
1191-1257.
38.
Parang K.,
Sun G. Design strategies for protein kinases inhibitors. Current Opinions
In Drug Discovery (2004) 7, 630-638.
39.
Nam N. H., Lee S., Ye G., Sun G., Parang K. ATP-phosphopeptide conjugates as
inhibitors of Src tyrosine kinases. Bioorg. Med. Chem. (2004)
12, 5753-5766.
40.
Nam N. H., Sardari S., Selecky M., Parang K. Carboxylic acids and phosphate
ester derivatives of fluconazole: synthesis and antifungal activities.
Bioorg. Med. Chem. (2004) 12, 6255-6269.
41.
Schmidt B., Jiricek J., Titz A., Ye G., Parang K. Copper dipicolinates as
peptidomimetic ligands for the Src SH2 domain. Bioorg. Med. Chem. Lett.
(2004) 14, 4203-4206.
42.
Nam N. H., Pitts R., Sun G., Sardari S., Tiemo A., Xie M., Yan B., Parang K.
Design of tetrapeptide ligands as inhibitors of the Src SH2 domain.
Bioorg. Med. Chem. (2004) 12, 779-787.
43.
Nam N.-H., Ye G., Sun G., Parang K. Conformationally constrained peptide
analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding.
J. Med. Chem. (2004) 47, 3131-3141.
44.
Carballeira N. M.,
Ortiz D., Parang K., Sardari S. Total synthesis and in vitro
antifungal activity of 2-methoxytetradecanoic acid. Arch. Pharm.-Pharm.
Med. Chem.
(2004)
337,
152-155.
45.
Force T.,
Kuida K., Parang K., Kyriakis J. M. Inhibitors of protein kinase signaling
pathways: emerging therapies for cardiovascular disease. Circulation
(2004)
109,
1196-1205.
46.
Lee S., Lin X., Nam N. H., Parang K., Sun G. Determination of the
substrate-docking site of protein tyrosine kinase Csk. Proc. Nat. Acad.
Sci. U.S.A. (2003) 100, 14707-14712.
47.
Sardari S., Pourmorad F., Tiemo A., Nam H., Parang K. Protein
kinases and their modulation in the central nervous system. Current
Medicinal Chemistry-CNS (2003) 3, 341-364.
48.
Nam N. H., Sardari S., Parang K. Reactions of solid supported
reagents and solid supports with alcohols and phenols through their hydroxyl
functional group. J. Comb. Chem. (2003) 5, 479-546.
49.
Parang K.,
Preface, Anti-HIV design, Bentham Science Publishers, Hilversum, Current
Pharm. Design (2003) 9, 22.
50.
Nam N. H., Parang K. Current Drug Targets for Anticancer Drug Discovery.
Current Drug Targets (2003), 4, 159-179.
51.
Parang K.,
Cole P. A. Bisubstrate inhibitors of protein kinases. Pharmacology and
Therapeutics (2002) 93, 145-157.
52.
Parang K.
Polymer-supported reagents for methylphosphorylation and phosphorylation of
Carbohydrates. Bioorg. Med. Chem. Lett. (2002) 12,
1863-1866.
53.
Parang K.,
Kohn J. A., Saldahna A., Cole P. A. Development of photo-crosslinking
reagents for protein kinase-substrate interactions. Febs Letters
(2002) 520, 156-160.
54.
Parang K.,
Preface, Anti-HIV design, Bentham Science Publishers, Hilversum, Current
Pharm. Design (2002) 8, 8.
55.
Parang K.,
Fournier E. J.-L., Hindsgaul O. A solid phase reagent for the capture
phosphorylation of carbohydrate and nucleosides. Org. Lett. (2001)
3, 307-309.
56.
Courtney A., Cole, P. A., Parang K., Ablooglu A., Kohanski R. Bisubstrate
inhibitors of kinases. PCT Int. Appl. WO 0170770 (2001) 39 pp.
57.
Parang K.,
Till J. H., Ablooglu A. J., Kohanski R. A., Hubbard S. R.,
Cole P. A. Mechanism-based design of a protein kinase inhibitor.
Nature Structural Biology (2001) 8, 37-41.
58.
Parang K.,
Wiebe L. I., Knaus E. E. Novel approaches in designing prodrugs of AZT.
Current Medicinal Chemistry (2000) 7, 995-1039.
59.
Kim K., Parang K., Lau O. D., Cole P. A. Tyrosine analogs as alternative
substrates for protein tyrosine kinase Csk: insights into substrate
selectivity and catalytic mechanism. Bioorg. Med. Chem. (2000)
8, 1263-1268.
60.
Ablooglu A. J., Till J. K., Kim K., Parang K., Cole P. A., Hubbard S. R.,
Kohanski R. A. Probing the catalytic mechanism of the insulin receptor
kinase with a tetrafluorotyrosine-containing peptide substrate. J. Biol.
Chem. (2000) 275, 30394-30398.
61.
Parang K.,
Wiebe L. I., Knaus E. E., Huang J. S., Tyrrell D. L. In vitro
anti-hepatitis B virus activities of 5’-O-myristoyl analogue
derivatives of 3’-fluoro-2’,3’-dideoxythymidine (FLT) and 3’-azido-2’,3’-dideoxythymidine
(AZT). J. Pharm. Pharmaceut. Sci. (1998) 1, 107-113.
62.
Parang K.,
Knaus E. E., Wiebe L. I. Synthesis, in vitro anti-HIV activity, and
biological stability of 5’-O-myristoyl analogue derivatives of
3’-fluoro-2’,3’-dideoxythymidine (FLT) as potential prodrugs of FLT.
Nucleosides & Nucleotides (1998) 17, 987-1008.
63.
Parang K.,
Wiebe L. I., Knaus E. E. In vivo pharmacokinetic parameters, liver
and brain uptake of (±)-3’-azido-2’,3’-dideoxy-5’-O-(2-bromomyristoyl)thymidine
as potential prodrug of 3’-azido-3’-deoxythymidine. J. Pharm. Pharmacol.
(1998) 50, 989-996.
64.
Parang K.,
Knaus E. E., Wiebe L. I. Synthesis, in vitro anti-HIV
structure-activity relationships and stability of 5’-O-myristoyl
analogue derivatives of 3’-azido-2’,3’-dideoxythymidine as potential
prodrugs of 3’-azido-2’,3’-dideoxythymidine (AZT). Antiviral. Chem.
Chemother. (1998) 9, 311-323.
65.
Parang, K.,
Wiebe, L. I., Knaus, E. E. Syntheses and biological evaluation of 5’-O-myristoyl
derivatives of thymidine against human immunodeficiency virus (HIV-1).
Antiviral. Chem. Chemother. (1997) 8, 417-427.
66.
Parang K.,
Wiebe L. I., Knaus E. E., Huang J. S., Tyrrell D. L., Csizmadia F. In
vitro antiviral activities of myristic acid analogs against human
immunodeficiency and hepatitis viruses. Antiviral Research (1997)
34, 75-90.
67.
Parang K.,
Knaus E. E., Wiebe L. I., Sardari S., Daneshtalab M., Csizmadia F. Synthesis
and antifungal activities of myristic acid analogs. Arch. Pharm.-Pharm.
Med. Chem. (1996) 329, 475-482.
68.
Sharifan A.,
Parang K., Zorrieh-Amirian H., Nazarinia M., Shafiee A. Synthesis of
1-substituted 1,2,4-triazoles, imidazoles and benzimidazoles. J. Heter.
Chem. (1994) 31, 1421-1423.
69.
Shafiee A.,
Parang K., Khazen M., Ghasemian F. Synthesis of substituted 2-(1-methyl-5-
nitro-2-imidazolyl)quinolines. J. Heter. Chem. (1992) 29,
1859-1861.
70.
Shafiee A.,
Pirouzzadeh B., Ghasemian F., Parang K. Synthesis of 2-acetyl-1-methyl
-5-nitroimidazole. J. Heter. Chem. (1992) 29,
1021-1023.
|